SCHEMBL2350320

SCHEMBL2350320

O=C(O)C(=O)CCc1cc2ccccc2[nH]1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 1/20 0.56
MTNR1B P49286 1/20 0.56
LOXL2 Q9Y4K0 1/20 0.50
PIN1 Q13526 1/20 0.50
KDM4E B2RXH2 2/20 0.49
MAPT P10636 1/20 0.49
DAO P14920 1/20 0.49
HPGD P15428 1/20 0.49
SRD5A2 P31213 1/20 0.49
HSD17B10 Q99714 1/20 0.49
HRH3 Q9Y5N1 2/20 0.48
ADAMTS4 O75173 1/20 0.46
FLT3 P36888 1/20 0.46
IDO1 P14902 2/20 0.45
HDAC3 O15379 2/20 0.45
HDAC1 Q13547 2/20 0.45
HDAC2 Q92769 2/20 0.45
HDAC8 Q9BY41 2/20 0.45
ALDH1A1 P00352 1/20 0.44
GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL606161 0.88 MTNR1A (0.60) MTNR1AMTNR1BLOXL2PIN1KDM4E
SCHEMBL29417817 0.88 MTNR1A (0.60) MTNR1AMTNR1BLOXL2PIN1KDM4E
SCHEMBL29272703 0.87 MTNR1A (0.59) MTNR1AMTNR1BLOXL2PIN1KDM4E
SCHEMBL28612721 0.84 MTNR1A (0.54) MTNR1AMTNR1BLOXL2PIN1KDM4E
Zinc Ion SCHEMBL30949479 0.84 MTNR1A (0.56) MTNR1AMTNR1BLOXL2PIN1KDM4E
SCHEMBL29383990 0.83 LOXL2 (0.53) MTNR1AMTNR1BLOXL2KDM4EMAPT
SCHEMBL4660280 0.83 LOXL2 (0.53) MTNR1AMTNR1BLOXL2KDM4EMAPT
SCHEMBL30052135 0.82 MTNR1A (0.57) MTNR1AMTNR1BLOXL2PIN1KDM4E
SCHEMBL664282 0.82 MTNR1A (0.57) MTNR1AMTNR1BLOXL2PIN1KDM4E
SCHEMBL12714834 0.82 MTNR1A (0.66) MTNR1AMTNR1BLOXL2PIN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1819697-B1 3-(INDOLYL)-4-ARYLMALEIMIDE DERIVATIVES AND THEIR USE AS ANGIOGENESIS INHIBITORS UNIV MAINZ JOHANNES GUTENBERG (DE) 2012-08-01 EP disclosed
US-8008320-B2 3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors Johannes Gutenberg-Universitatis (DE) 2011-08-30 US disclosed
US-20090306124-A1 3-(INDOLYL)-4-ARYLMALEIMIDE DERIVATIVES AND THEIR USE AS ANGIOGENESIS INHIBITORS JOHANNES GUTENBERG-UNIVERSITAT MAINZ (DE) 2009-12-10 US disclosed
EP-1819697-A1 3-(INDOLYL)-4-ARYLMALEIMIDE DERIVATIVES AND THEIR USE AS ANGIOGENESIS INHIBITORS Johannes Gutenberg-Universität Mainz (DE) 2007-08-22 EP disclosed
WO-2006061212-A1 3-(INDOLYL)-4-ARYLMALEIMIDE DERIVATIVES AND THEIR USE AS ANGIOGENESIS INHIBITORS Johannes Gutenberg-Universität Mainz (DE) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306124-A1 3-(INDOLYL)-4-ARYLMALEIMIDE DERIVATIVES AND THEIR USE AS ANGIOGENESIS INHIBITORS FLT4, KDR, FLT1 MTNR1A 351/4885MTNR1B 293/4885LOXL2 949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.